Loading clinical trials...
Loading clinical trials...
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT06681623 · Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
NCT06251986 · Relapsing Forms of Multiple Sclerosis
NCT05083923 · Relapsing Forms of Multiple Sclerosis
NCT01201356 · Relapsing Forms of Multiple Sclerosis
NCT01873417 · Relapsing Forms of Multiple Sclerosis
Novartis Investigative Site
Lutherville, Maryland
Novartis Investigative Site
Parkville, Victoria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions